Bionano Genomics files S-1 to register 1.3 million warrant shares

Bionano Genomics, Inc. filed a Form S-1 registration statement with the Securities and Exchange Commission on October 27, 2026. The filing covers 1,332,632 shares of common stock issuable upon exercise of warrants originally offered under the company's previous Form S-3 shelf registration (No. 333-270459), which was declared effective on May 10, 2023 and expires on November 6, 2026.¹ Bionano said it is filing the new S-1 solely to ensure an effective registration statement covers exercise of the outstanding warrants.¹

The warrants break into four groups. These include 661,377 shares under 2025 Purchase Warrants priced at $15.120 per share, 164,684 shares under Series C Warrants at $18.234, 145,560 shares under 2024 Purchase Warrants at $61.20, and 361,011 shares under 2023 Purchase Warrants at $191.13.¹ The 2025 Purchase Warrants became exercisable June 11, 2025 and expire five years later; the Series C Warrants became exercisable January 15, 2025; the 2024 Purchase Warrants were exercisable immediately upon issuance on April 8, 2024; and the 2023 Purchase Warrants were exercisable immediately upon issuance on October 13, 2023, each expiring on its five-year anniversary.¹

If all warrants are exercised in full, the company estimates proceeds of approximately $90 million, which it intends to use for general corporate purposes including working capital, research and development, and capital expenditures.¹ Bionano's common stock trades on the Nasdaq Capital Market under "BNGO," closing at $1.16 per share on October 26, 2026.¹

Common stock outstanding before the offering stood at 13,976,957 shares, rising to 15,309,589 shares if the warrants are fully exercised.¹ Bionano noted its stock price ranged between a high of $1.87 on October 28, 2025 and a low of $1.06 on July 30, 2026 over the trailing 12 months.¹